Quick Takeaways
- PHVS - Pharvaris N.V. has 13 insiders with reported activity on this page.
- Net insider value flow over the last year: -$5,031,145.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 13 Insiders of Pharvaris N.V.
- Symbol
- PHVS on Nasdaq
- Location
- Leiden
What Changed
- Buy value: ; sell value: $5,031,144.
- Net share flow: -168,625.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$5,031,145.
Buys
$0
Shares: 0
Insiders: 0
Sells
$5,031,145
Shares: 168,625
Insiders: 4
Net
-$5,031,145
Shares: -168,625
Insiders: -4
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 168,625 | $0 | $5,031,145 | -$5,031,145 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Pharvaris N.V. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Berndt Modig | Chief Executive Officer, Director | $57,198,593 | -$712,840 | -1.2% | Mixed | 16 Apr 2026 |
| Anne Lesage | Chief Early Development | $14,571,265 | -$1,901,696 | -12% | Mixed | 29 Apr 2026 |
| Johannes Gerardus Christiaan Petrus Schikan | Director | $11,021,577 | -$1,209,926 | -9.9% | Filing P/S | 29 Apr 2026 |
| David W. Nassif | Cfo / Clo | $3,098,125 | Mixed | 18 Mar 2026 | ||
| Annick Deschoolmeester | Chief Human Resources Officer | $2,313,825 | Mixed | 18 Mar 2026 | ||
| Peng Lu | Chief Medical Officer | $1,860,460 | -$1,206,683 | -39% | Median | 11 May 2026 |
| David P. Meeker | Director | $1,629,175 | Mixed | 18 Mar 2026 | ||
| Wim Souverijns | Chief Commercial Officer | $1,377,775 | Mixed | 18 Mar 2026 | ||
| Stefan Andreas Abele | Chief Technical Ops Officer | $1,365,744 | Mixed | 27 Mar 2026 | ||
| Anna Nijdam | Principal Accounting Officer | $1,358,085 | Mixed | 14 Apr 2026 | ||
| Robert Glassman | Director | $379,175 | Mixed | 17 Mar 2026 | ||
| Elisabeth Bjork | Director | $379,175 | Mixed | 18 Mar 2026 | ||
| Viviane Monges | Director | $366,350 | Mixed | 17 Mar 2026 |
Top shareholders of Pharvaris N.V. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| GENERAL ATLANTIC, L.P. |
13F
|
Individual |
12%
|
8,031,252
|
$226,882,869 | — | 31 Mar 2026 | |
| FMR LLC |
13F
|
Company |
9.6%
|
6,284,472
|
$177,536,335 | — | 31 Mar 2026 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
7.3%
|
4,778,581
|
$134,994,913 | — | 31 Mar 2026 | |
| venBio Partners LLC |
13F
|
Company |
7.1%
|
4,639,304
|
$131,060,338 | — | 31 Mar 2026 | |
| VIKING GLOBAL INVESTORS LP |
13F
13D/G
|
Company |
5.6%
from 13D/G
|
3,653,310
|
$103,206,008 | — | 31 Mar 2026 | |
| EQT Fund Management S.a r.l. |
13F
|
Company |
5.2%
|
3,424,609
|
$96,745,204 | — | 31 Mar 2026 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
4.8%
|
3,126,042
|
$88,310,687 | — | 31 Mar 2026 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
4.1%
|
2,675,509
|
$75,583,129 | — | 31 Mar 2026 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
3.2%
|
2,118,900
|
$59,858,926 | — | 31 Mar 2026 | |
| Berndt Modig |
3/4/5
|
Chief Executive Officer, Director |
3.1%
|
2,039,792
|
$57,198,593 | -$712,840 | 16 Apr 2026 | |
| Commodore Capital LP |
13F
|
Company |
2.9%
|
1,918,970
|
$54,210,903 | — | 31 Mar 2026 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
3.8%
|
2,047,620
|
$51,436,214 | $0 | 30 Jun 2025 | |
| Novo Holdings A/S |
13F
|
Company |
2.7%
|
1,750,000
|
$49,437,500 | — | 31 Mar 2026 | |
| Bain Capital Life Sciences Fund, L.P. |
13D/G
|
— |
2.5%
|
1,640,817
|
$41,020,425 | -$5,670,300 | 31 Dec 2025 | |
| Saturn V Capital Management LP |
13F
|
Company |
1.8%
|
1,201,402
|
$33,939,606 | — | 31 Mar 2026 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.5%
|
1,007,016
|
$28,448,202 | — | 31 Mar 2026 | |
| Cormorant Asset Management, LP |
13F
|
Company |
1.5%
|
1,000,000
|
$28,250,000 | — | 31 Mar 2026 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
1.3%
|
818,328
|
$23,117,766 | — | 31 Mar 2026 | |
| 5AM Venture Management, LLC |
13F
|
Company |
1.2%
|
797,600
|
$22,532,200 | — | 31 Mar 2026 | |
| Polar Capital Holdings Plc |
13F
|
Company |
1.2%
|
781,016
|
$22,063,702 | — | 31 Mar 2026 | |
| BlackRock, Inc. |
13F
|
Company |
1.2%
|
757,213
|
$21,391,267 | — | 31 Mar 2026 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
1.1%
|
702,052
|
$19,832,969 | — | 31 Mar 2026 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.99%
|
645,533
|
$18,236,307 | — | 31 Mar 2026 | |
| Kynam Capital Management, LP |
13F
|
Company |
0.98%
|
640,395
|
$18,091,159 | — | 31 Mar 2026 | |
| Anne Lesage |
3/4/5
|
Chief Early Development |
—
mixed-class rows
|
593,257
mixed-class rows
|
$14,571,265 | -$1,901,696 | 29 Apr 2026 | |
| Patient Square Capital LP |
13F
|
Company |
0.76%
|
493,000
|
$13,927,250 | — | 31 Mar 2026 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.75%
|
486,856
|
$13,753,683 | — | 31 Mar 2026 | |
| Elmind Capital, LP |
13F
|
Company |
0.73%
|
475,750
|
$13,439,938 | — | 31 Mar 2026 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.71%
|
462,251
|
$13,058,591 | — | 31 Mar 2026 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.68%
|
442,256
|
$12,494,000 | — | 31 Mar 2026 | |
| Eversept Partners, LP |
13F
|
Company |
0.62%
|
406,960
|
$11,496,620 | — | 31 Mar 2026 | |
| Johannes Gerardus Christiaan Petrus Schikan |
3/4/5
|
Director |
0.54%
|
355,167
|
$11,021,577 | -$1,209,926 | 29 Apr 2026 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.57%
|
375,000
|
$10,593,750 | — | 31 Mar 2026 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.49%
|
321,157
|
$9,072,685 | — | 31 Mar 2026 | |
| Tetragon Partners GP Ltd |
13F
|
Company |
0.34%
|
221,611
|
$6,260,511 | — | 31 Mar 2026 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.31%
|
205,400
|
$5,802,550 | — | 31 Mar 2026 | |
| Kalehua Capital Management LLC |
13F
|
Company |
0.3%
|
198,772
|
$5,615,309 | — | 31 Mar 2026 | |
| Foresite Capital Management V, LLC |
13F
|
Company |
0.3%
|
194,125
|
$5,484,031 | — | 31 Mar 2026 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.28%
|
181,946
|
$5,139,974 | — | 31 Mar 2026 | |
| Seven Fleet Capital Management LP |
13F
|
Company |
0.26%
|
172,731
|
$4,879,651 | — | 31 Mar 2026 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.26%
|
168,630
|
$4,763,798 | — | 31 Mar 2026 | |
| Jones Hill Capital LP |
13F
|
Company |
0.26%
|
167,014
|
$4,718,146 | — | 31 Mar 2026 | |
| Octagon Capital Advisors LP |
13F
|
Company |
0.25%
|
165,000
|
$4,661,250 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0.25%
|
164,323
|
$4,642,125 | — | 31 Mar 2026 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.24%
|
157,117
|
$4,438,555 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
0.23%
|
152,945
|
$4,320,696 | — | 31 Mar 2026 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.24%
|
158,019
|
$4,312,339 | — | 31 Mar 2026 | |
| DV Trading LLC |
13F
|
Company |
0.22%
|
143,966
|
$4,067,040 | — | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.22%
|
142,929
|
$4,037,745 | — | 31 Mar 2026 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.19%
|
126,076
|
$3,561,647 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for Pharvaris N.V.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Peng Lu | PHVS | Common Stock | Tax liability | -0.18% | -117 | 65,857 | 12 May 2026 | Direct | ||
| Peng Lu | PHVS | Common Stock | Tax liability | -0.16% | -109 | 65,974 | 11 May 2026 | Direct | ||
| Peng Lu | PHVS | Common Stock | Sale | -17.6% | $427,419 | $30.17 | -14,166 | 66,083 | 01 May 2026 | Direct |
| Peng Lu | PHVS | Common Stock | Options Exercise | 21.4% | 14,166 | 80,249 | 01 May 2026 | Direct | ||
| Peng Lu | PHVS | Stock Option (Right to Buy) | Options Exercise | -6.45% | -14,166 | 205,308 | 01 May 2026 | Direct | ||
| Johannes Gerardus Christiaan Petrus Schikan | PHVS | Common Stock | Sale | -7.57% | $881,380 | $30.32 | -29,070 | 355,167 | 30 Apr 2026 | Direct |
| Anne Lesage | PHVS | Common Stock | Sale | -12.5% | $580,909 | $30.26 | -19,200 | 133,969 | 30 Apr 2026 | By GrayMatters Consulting BV |
| Anne Lesage | PHVS | Common Stock | Sale | -27.8% | $656,551 | $30.26 | -21,700 | 56,450 | 30 Apr 2026 | Direct |
| Anne Lesage | PHVS | Common Stock | Options Exercise | 41.1% | 21,700 | 74,450 | 30 Apr 2026 | Direct | ||
| Anne Lesage | PHVS | Stock Option (Right to Buy) | Options Exercise | -70.5% | -21,700 | 9,072 | 30 Apr 2026 | Direct | ||
| Peng Lu | PHVS | Common Stock | Sale | -18.5% | $453,627 | $30.24 | -15,000 | 66,083 | 30 Apr 2026 | Direct |
| Peng Lu | PHVS | Common Stock | Options Exercise | 22.7% | 15,000 | 81,083 | 30 Apr 2026 | Direct | ||
| Peng Lu | PHVS | Stock Option (Right to Buy) | Options Exercise | -6.4% | -15,000 | 219,474 | 30 Apr 2026 | Direct | ||
| Johannes Gerardus Christiaan Petrus Schikan | PHVS | Common Stock | Sale | -0.99% | $115,165 | $30.07 | -3,830 | 384,237 | 29 Apr 2026 | Direct |
| Anne Lesage | PHVS | Common Stock | Sale | -2.36% | $111,229 | $30.06 | -3,700 | 153,169 | 29 Apr 2026 | By GrayMatters Consulting BV |
| Anne Lesage | PHVS | Common Stock | Sale | -6.15% | $111,280 | $30.08 | -3,700 | 56,450 | 29 Apr 2026 | Direct |
| Anne Lesage | PHVS | Common Stock | Options Exercise | 6.55% | 3,700 | 60,150 | 29 Apr 2026 | Direct | ||
| Anne Lesage | PHVS | Stock Option (Right to Buy) | Options Exercise | -22.5% | -3,700 | 12,772 | 29 Apr 2026 | Direct | ||
| Peng Lu | PHVS | Common Stock | Sale | -5.65% | $112,232 | $30.06 | -3,733 | 62,350 | 29 Apr 2026 | Direct |
| Peng Lu | PHVS | Common Stock | Options Exercise | 5.65% | 3,733 | 69,816 | 29 Apr 2026 | Direct | ||
| Peng Lu | PHVS | Stock Option (Right to Buy) | Options Exercise | -1.57% | -3,733 | 234,474 | 29 Apr 2026 | Direct | ||
| Johannes Gerardus Christiaan Petrus Schikan | PHVS | Common Stock | Sale | -0.03% | $3,003 | $30.03 | -100 | 388,067 | 23 Apr 2026 | Direct |
| Anne Lesage | PHVS | Common Stock | Sale | -0.18% | $3,003 | $30.03 | -100 | 56,450 | 23 Apr 2026 | Direct |
| Anne Lesage | PHVS | Common Stock | Options Exercise | 0.18% | 100 | 56,550 | 23 Apr 2026 | Direct | ||
| Anne Lesage | PHVS | Common Stock | Sale | -0.06% | $3,003 | $30.03 | -100 | 156,869 | 23 Apr 2026 | GrayMatters Consulting B.V. |
| Anne Lesage | PHVS | Stock Option (Right to Buy) | Options Exercise | -0.63% | -100 | 15,872 | 23 Apr 2026 | Direct | ||
| Peng Lu | PHVS | Common Stock | Sale | -0.15% | $3,003 | $30.03 | -100 | 66,083 | 23 Apr 2026 | Direct |
| Peng Lu | PHVS | Common Stock | Options Exercise | 0.15% | 100 | 66,183 | 23 Apr 2026 | Direct | ||
| Peng Lu | PHVS | Stock Option (Right to Buy) | Options Exercise | -0.09% | -100 | 106,207 | 23 Apr 2026 | Direct | ||
| Johannes Gerardus Christiaan Petrus Schikan | PHVS | Common Stock | Sale | -1.77% | $210,379 | $30.05 | -7,000 | 388,167 | 22 Apr 2026 | Direct |
| Anne Lesage | PHVS | Common Stock | Sale | -4.27% | $210,358 | $30.05 | -7,000 | 156,969 | 22 Apr 2026 | GrayMatters Consulting B.V. |
| Anne Lesage | PHVS | Common Stock | Sale | -11.7% | $225,362 | $30.05 | -7,500 | 56,450 | 22 Apr 2026 | Direct |
| Anne Lesage | PHVS | Common Stock | Options Exercise | 13.4% | 7,500 | 63,450 | 22 Apr 2026 | Direct | ||
| Anne Lesage | PHVS | Stock Option (Right to Buy) | Options Exercise | -32% | -7,500 | 15,972 | 22 Apr 2026 | Direct | ||
| Peng Lu | PHVS | Common Stock | Sale | -9.58% | $210,402 | $30.05 | -7,001 | 66,083 | 22 Apr 2026 | Direct |
| Peng Lu | PHVS | Common Stock | Options Exercise | 10.6% | 7,001 | 73,084 | 22 Apr 2026 | Direct | ||
| Peng Lu | PHVS | Stock Option (Right to Buy) | Options Exercise | -6.18% | -7,001 | 106,307 | 22 Apr 2026 | Direct | ||
| Peng Lu | PHVS | Common Stock | Tax liability | -0.34% | -226 | 66,083 | 16 Apr 2026 | Direct | ||
| Berndt Modig | PHVS | Common Stock | Sale | -1.61% | $65,559 | $28.60 | -2,292 | 139,792 | 16 Apr 2026 | Direct |
| Anna Nijdam | PHVS | Common Stock | Tax liability | -1.11% | -548 | 48,940 | 11 Apr 2026 | Direct | ||
| Berndt Modig | PHVS | Common Stock | Sale | -14.1% | $647,281 | $27.74 | -23,333 | 142,084 | 09 Apr 2026 | Direct |
| Anna Nijdam | PHVS | Common Stock | Tax liability | -2.3% | -1,167 | 49,488 | 06 Apr 2026 | Direct | ||
| Anna Nijdam | PHVS | Common Stock | Tax liability | -2.25% | -1,164 | 50,655 | 01 Apr 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.